Multaq Dosage
Generic name: DRONEDARONE 400mg
Dosage form: tablet, film coated
Drug class: Group III antiarrhythmics
Medically reviewed by Drugs.com. Last updated on May 29, 2025.
The recommended dosage of MULTAQ is 400 mg twice daily in adults. MULTAQ should be taken as one tablet with the morning meal and one tablet with the evening meal.
Treatment with Class I or III antiarrhythmics (e.g., amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) or drugs that are strong inhibitors of CYP3A (e.g., ketoconazole) must be stopped before starting MULTAQ.
Verify that females of reproductive potential are not pregnant prior to initiating MULTAQ.
More about Multaq (dronedarone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (43)
- Drug images
- Side effects
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: group III antiarrhythmics
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Cardizem
Cardizem is used to treat hypertension (high blood pressure), angina (chest pain), and heart rhythm ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Lanoxin
Lanoxin (digoxin) is used to treat congestive heart failure and atrial fibrillation. Includes ...
Edoxaban
Edoxaban is used for atrial fibrillation, deep vein thrombosis, prevention of thromboembolism in ...
Propafenone
Propafenone is used for atrial fibrillation, atrial flutter, ventricular tachycardia ...
Sotalol
Sotalol is a beta-blocker with antiarrhythmic properties that affects the heart and circulation ...
Flecainide
Flecainide is used for atrial fibrillation, atrial flutter, paroxysmal supraventricular ...
Rivaroxaban
Rivaroxaban is used for atrial fibrillation, cardiovascular risk reduction, congenital heart ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
